NECTIVE FORTE

Indications

• COVID-19
• SARS-CoV-2 infection

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations based on clinical guidelines.

Mechanism of action

Nirmatrelvir is a selective inhibitor of the SARS-CoV-2 main protease (Mpro). By binding to the active site of this enzyme, nirmatrelvir prevents the cleavage of viral polyproteins, which is essential for the maturation of the virus. This ultimately inhibits viral replication.

Pharmacodynamics

Nirmatrelvir exhibits antiviral activity by specifically targeting the main protease of SARS-CoV-2. The inhibition of Mpro disrupts the viral life cycle, reducing the viral load in the body. The potency of nirmatrelvir is enhanced by ritonavir, which prolongs its action by slowing its metabolism.

Pharmacokinetics

Nirmatrelvir is rapidly absorbed after oral administration. The bioavailability is increased when combined with ritonavir, which inhibits CYP3A4, the enzyme responsible for nirmatrelvir's metabolism. The half-life of nirmatrelvir is approximately 7 hours, allowing for twice-daily dosing. It is primarily excreted via feces and urine, with minimal renal clearance.

Interactions

• nirmatrelvir boosted with ritonavir and containing ethinylestradiol: Unknown (decreases concentration)

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Schizophrenia
• Bipolar disorder
• Major depressive disorder (as an adjunct)
• Treatment-resistant depression
• Other psychotic disorders

Dosage

Children: Refer to the BNF for Children for age-specific dosing recommendations.

Adults: Refer to specific clinical guidelines and consider individual patient factors for appropriate dosing.

Mechanism of action

Phase acts primarily as a dopamine D2 receptor antagonist, which reduces dopaminergic transmission in the central nervous system. Additionally, it has effects on serotonin receptors, particularly the 5-HT2A receptor, which may contribute to its antipsychotic effects and help mitigate side effects associated with dopamine antagonism. This dual action helps balance neurotransmitter systems, thereby improving overall clinical outcomes in patients with psychotic disorders.

Pharmacodynamics

Phase has a complex pharmacodynamic profile, characterized by its ability to alter mood, perception, and behavior. The blockade of D2 receptors is linked to the reduction of positive symptoms of schizophrenia, such as hallucinations and delusions. The antagonism of serotonin receptors is associated with the alleviation of negative symptoms, such as social withdrawal and apathy. The therapeutic effects, alongside potential side effects, are closely related to the drug's receptor binding affinities and the resulting changes in neurotransmitter dynamics within the brain.

Pharmacokinetics

Phase is typically administered orally and demonstrates significant first-pass metabolism, resulting in variable bioavailability. Peak plasma concentrations are reached within several hours after administration. The drug is primarily metabolized in the liver via cytochrome P450 enzymes, with multiple metabolites contributing to its overall activity. Elimination occurs predominantly through renal excretion, with a half-life that allows for once or twice daily dosing in most cases. Factors such as age, liver function, and concomitant medications can influence its pharmacokinetic profile.

Pregnancy

The effects of phase during pregnancy are not well studied; caution is advised.

Breast-feeding

The effects of phase during breastfeeding are not well established; caution is advised.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.